AMAG Pharmaceuticals, Inc. (AMAG) on Focus After Trading At 52-Week Highs

May 18, 2018 - By Carrie Sands

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Logo

Investors sentiment decreased to 0.9 in Q4 2017. Its down 0.54, from 1.44 in 2017Q3. It dropped, as 29 investors sold AMAG Pharmaceuticals, Inc. shares while 53 reduced holdings. 24 funds opened positions while 50 raised stakes. 37.72 million shares or 5.64% less from 39.98 million shares in 2017Q3 were reported.
Teacher Retirement Of Texas, Texas-based fund reported 12,239 shares. Whittier Trust reported 2,292 shares. Eii Mgmt reported 119,690 shares or 0.67% of all its holdings. Ameritas Investment Prns reported 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). State Of Wisconsin Inv Board owns 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 26,000 shares. Macquarie Gru Ltd reported 6,600 shares. Envestnet Asset Management holds 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 122 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Invesco Ltd stated it has 145,481 shares. Financial Bank Of Mellon Corporation holds 0% or 637,748 shares in its portfolio. 214,150 were reported by Tocqueville Asset L P. Jane Street Ltd accumulated 12,115 shares. Barclays Public Limited Liability Com holds 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) or 27,812 shares. Stratos Wealth Limited reported 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Moreover, Federated Investors Inc Pa has 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 94,659 shares.

Since February 23, 2018, it had 0 insider buys, and 1 sale for $16,016 activity.

The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) hit a new 52-week high and has $26.18 target or 6.00 % above today’s $24.70 share price. The 7 months bullish chart indicates low risk for the $847.87 million company. The 1-year high was reported on May, 18 by If the $26.18 price target is reached, the company will be worth $50.87 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.20% or $0.05 during the last trading session, reaching $24.7. About 125,379 shares traded. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has declined 16.25% since May 18, 2017 and is downtrending. It has underperformed by 27.80% the S&P500.

Analysts await AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to report earnings on August, 2. They expect $-0.22 earnings per share, up 45.00 % or $0.18 from last year’s $-0.4 per share. After $-1.59 actual earnings per share reported by AMAG Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -86.16 % EPS growth.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage

Among 7 analysts covering Amag Pharmaceuticals (NASDAQ:AMAG), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. Amag Pharmaceuticals has $25.0 highest and $15.0 lowest target. $24.29’s average target is -1.66% below currents $24.7 stock price. Amag Pharmaceuticals had 14 analyst reports since December 7, 2017 according to SRatingsIntel. As per Friday, March 23, the company rating was maintained by FBR Capital. Cantor Fitzgerald maintained AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) rating on Wednesday, February 14. Cantor Fitzgerald has “Hold” rating and $17.0 target. The firm earned “Hold” rating on Thursday, January 18 by Piper Jaffray. As per Thursday, February 1, the company rating was maintained by Cantor Fitzgerald. The rating was upgraded by Janney Capital on Thursday, February 15 to “Buy”. Cantor Fitzgerald maintained it with “Hold” rating and $17.0 target in Tuesday, February 27 report. The rating was maintained by Jefferies on Thursday, February 15 with “Buy”. Cowen & Co maintained AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Tuesday, February 27 with “Hold” rating. The rating was maintained by Morgan Stanley on Wednesday, February 28 with “Overweight”. The stock has “Hold” rating by Piper Jaffray on Wednesday, February 14.

More notable recent AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) news were published by: which released: “AMAG Pharmaceuticals to Present at Upcoming Investor Conferences” on April 27, 2018, also with their article: “AMAG Pharmaceuticals Appoints J. Alan Butcher as Executive Vice President and Chief Business Officer” published on May 02, 2018, published: “Benzinga’s Daily Biotech Pulse: AstraZeneca’s Q1, Novartis-Amgen Migraine Drug Approved” on May 18, 2018. More interesting news about AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) were released by: and their article: “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” published on May 11, 2018 as well as‘s news article titled: “AMAG Pharmaceuticals Announces First Quarter 2018 Financial Results and Raises Full Year Financial Guidance” with publication date: May 03, 2018.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. The company has market cap of $847.87 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: